anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/EP94/02567 Sec. 371 Date Feb. 16, 1996 Sec. 102(e) Date Feb. 16, 1996 PCT Filed Aug. 3, 1994 PCT Pub. No. WO95/05844 PCT Pub. Date Mar. 2, 1995A method for treating or preventing mastitis in cows is disclosed. The method contemplates the intramammary injection or dipping the teat with Gallidermin and/or Epidermin or one of their pharmaceutically acceptable acid salts. Gallidermin and/or Epidermin or one of their pharmaceutically acceptable acid salts can be administered prior to infection to effectively suppress the rate, severity, and duration of subsequent bacterial infection, or can be administered subsequent to infection to effectively treat mastitis.
This is a cross-sectional, controlled study designed to investigate whether Transforming Growth Factor-beta (TGF-beta) mediates increased asthmatic epithelial susceptibility to respiratory syncytial virus (RSV) infection by examining responses to RSV infection in epithelial cells cultured from asthmatic and non-asthmatic participants. Non-smoking healthy adults and mild asthmatics, aged 18-60 years old, will be recruited to participate. Potential participants will be prescreened and scheduled for a final eligibility visit that will include medical history review, vital signs, physical examination, blood draw, and pulmonary function tests (PFTs). After eligibility is confirmed, the participant will be scheduled for bronchoscopy. During the bronchoscopy, bronchial epithelia and alveolar macrophages will be obtained from the participant for analysis. Alveolar macrophages will be evaluated ex-vivo for inflammatory activity at baseline and after stimulation.

The primary objective of the laboratory analysis is to determine if TGF-beta mediates increased asthmatic epithelial susceptibility to RSV infection. The study has three aims which are interrelated: 1) To determine if asthmatic bronchial epithelia express more TGF-beta than normal epithelia; 2) to determine if RSV replication is greater in asthmatic epithelia than normal epithelia; and 3) to determine if TGF-beta mediates asthmatic bronchial epithelial susceptibility to RSV infections.
This is a multicenter, multiple ascending dose, open-label study (Core Study) with an Extension Phase. The Core Study consisted of 2 phases, the Pretreatment Phase and the Treatment Phase. The Pretreatment Phase lasted up to 2 weeks in duration, during which participants were assessed for their eligibility to participate in the study. The Treatment Phase consisted of 3 periods: Titration (7 weeks), Maintenance (4 weeks), and Follow-up (4 weeks; only for those participants not rolling over into the Extension Phase after completing the Treatment Phase and for those participants who discontinued from the study). All subjects who completed all scheduled visits up to and including the final visit of the Treatment Phase (Core Study) were eligible to participate in the Extension Phase of the study. The Extension Phase consisted of 2 periods: Maintenance (41 weeks) and Follow-up (4 weeks).
Monotherapy and Adjunctive Therapy

Adult Patients

The recommended initial dosage of APTIOM is 400 mg administered orally once daily. For some patients, treatment may be initiated at 800 mg once daily if the need for seizure reduction outweighs an increased risk of adverse reactions during initiation [see Adverse Reactions (6.1)]. Dosage should be increased in weekly increments of 400 mg to 600 mg, based on clinical response and tolerability, to a recommended maintenance dosage of 800 mg to 1600 mg once daily. For patients on APTIOM monotherapy, the 800 mg once daily maintenance dose should generally be considered in patients who are unable to tolerate a 1200 mg daily dose. For patients on APTIOM adjunctive therapy, the 1600 mg daily dose should generally be considered in patients who did not achieve a satisfactory response with a 1200 mg daily dose. 

Pediatric Patients (4 to 17 Years of Age)

In pediatric patients 4 to 17 years of age, the recommended dosing regimen is dependent upon body weight and is administered orally once daily. The recommended initial dosage of APTIOM is shown in Table 1. Dosage should be increased based on clinical response and tolerability, no more frequently than once per week. Titration increments should not exceed those shown in Table 1. The daily maintenance dosage should not exceed the maintenance dosage for each body weight range shown in Table 1.
Obesity and food addiction are associated with distinct brain signatures related to reward processing, and early life adversity (ELA) also increases alterations in these same reward regions. However, the neural mechanisms underlying the effect of early life adversity on food addiction are unknown. Therefore, the aim of this study was to examine the interactions between ELA, food addiction, and brain morphometry in individuals with obesity. 114 participants with high body mass index (BMI) underwent structural MRIs, and completed several questionnaires (e.g., Yale Food Addiction Scale (YFAS), Brief Resilience Scale (BRS), Early Traumatic Inventory (ETI)). Freesurfer 6 was applied to generate the morphometry of brain regions. A multivariate pattern analysis was used to derive brain morphometry patterns associated with food addiction. General linear modeling and mediation analyses were conducted to examine the effects of ELA and resilience on food addiction in individuals with obesity. Statistical significance was determined at a level of p < 0.05. High levels of ELA showed a strong association between reward control brain signatures and food addiction (p = 0.03). Resilience positively mediated the effect of ELA on food addiction (B = 0.02, p = 0.038). Our findings suggest that food addiction is associated with brain signatures in motivation and reward processing regions indicative of dopaminergic dysregulation and inhibition of cognitive control regions. These mechanistic variabilities along with early life adversity suggest increased vulnerability to develop food addiction and obesity in adulthood, which can buffer by the neuroprotective effects of resilience, highlighting the value of incorporating cognitive appraisal into obesity therapeutic regimens.
Immune thrombocytopenia (ITP) is a disorder that can lead to easy or excessive bruising and bleeding. Approximately two-thirds of patients achieve remission after/during first-line therapies. However, the other part of patients could not achieve durable remission or even refractory to initial treatments. Those cases, known as relapse/refractory Immune thrombocytopenia (R/R ITP), undergo the heavy burden of disease which decreases the quality of life. Lots of pathogeneses take part in the occurrence of R/R ITP, and the most important one of them is antibody-mediated immune platelet destruction. As far as it is known，human platelet autoantibodies are mainly secreted by plasma cells, especially long-lived plasma cells. Researchers want to explore that can BCMA CAR-T help R/R ITP patients increase platelet count, reduce bleeding episodes and the dose of concomitant medications.
N-myc downstream-regulated gene 2 (NDRG2) has been recognised as a negative regulator of the progression of numerous tumours, yet its specific role in small-cell lung carcinoma (SCLC) is not fully understood. The purpose of the current study was to investigate the biological role and mechanism of NDRG2 in SCLC. Initial investigation using the Gene Expression Omnibus (GEO) dataset revealed marked downregulation of NDRG2 transcripts in SCLC. The decreased abundance of NDRG2 in SCLC was verified by examining clinical specimens. Increasing NDRG2 expression in SCLC cell lines caused significant changes in cell proliferation, cell cycle progression, colony formation, and chemosensitivity. NDRG2 overexpression decreased the levels of phosphorylated PTEN, AKT and mTOR. In PTEN-depleted SCLC cells, the upregulation of NDRG2 did not result in any noticeable impact on AKT or mTOR activation. Additionally, the reactivation of AKT reversed the antitumour effects of NDRG2 in SCLC cells. Notably, increasing NDRG2 expression retarded the growth of SCLC cell-derived xenografts in vivo. In conclusion, NDRG2 serves as an inhibitor of SCLC, and its cancer-inhibiting effects are achieved through the suppression of AKT/mTOR via the activation of PTEN. This work suggests that NDRG2 is a potential druggable target for SCLC treatment.
Age range of 18 to 44 years olds The initial dose of rocuronium for pre-injection was set at 0.04mg/kg according to previous literature and preliminary test results. The dose of rocuronium was according to the patients' myofibrillation level. If there is no myofibrillation (negative reaction), the dose of rocuronium in the next patient will be reduced until the patient has myofibrillation. If there is myofibrillation (positive reaction), the dose of rocuronium will be increased in the next patient until the patient is no fibrillation.
The purpose of this study is to determine the phytochemical content and biological activities of the Astragalus gombo (endemic specie). While identification and quantification of individual secondary metabolites were performed by analysis HPLC. Antioxidant (DPPH and FRAP), anti-inflammatory, anti-hemolytic and antibacterial activities were evaluated. For analysis HPLC, we obtained 65 peaks and identified 6 major bioactive compounds. The total concentration in polyphenols, flavonoids and condensed tannins varied respectively from 66.306±0.88 mg GA eq/g, 34.312±1.4 mg Q eq/g and 5.343±2.74 mg Ca eq/g. In terms of antioxidant activity, we found that this extract had high inhibitory ratios equivalent to IC50=62.813±0.006 µg/mL for DPPH and IC50=19.375±0.041 µg/mL for FRAP.  A high anti-inflammatory activity was estimated at 1615.81µg/mL, and a weak anti-hemolytic activity, the other hand the antibacterial activity is somewhat moderate against the five strains studied. This study demonstrated that the aqueous extract of A. gombo from El Oued region has tremendous antioxidant, anti-inflammatory and antibacterial abilities.
The safety and efficacy of NEUPOGEN to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs were established in a randomized‚ double-blind‚ placebo-controlled trial conducted in patients with small cell lung cancer (Study 1).

In Study 1, patients received up to 6 cycles of intravenous chemotherapy including intravenous cyclophosphamide and doxorubicin on day 1; and etoposide on days 1, 2, and 3 of 21 day cycles. Patients were randomized to receive NEUPOGEN (n = 99) at a dose of 230 mcg/m2 (4 to 8 mcg/kg/day) or placebo (n = 111). Study drug was administered subcutaneously daily beginning on day 4, for a maximum of 14 days. A total of 210 patients were evaluable for efficacy and 207 were evaluable for safety. The demographic and disease characteristics were balanced between arms with a median age of 62 (range 31 to 80) years; 64% males; 89% Caucasian; 72% extensive disease and 28% limited disease.

The main efficacy endpoint was the incidence of febrile neutropenia. Febrile neutropenia was defined as an ANC < 1,000/mm3 and temperature > 38.2°C. Treatment with NEUPOGEN resulted in a clinically and statistically significant reduction in the incidence of infection‚ as manifested by febrile neutropenia, 40% for NEUPOGEN-treated patients and 76% for placebo-treated patients (p < 0.001). There were also statistically significant reductions in the incidence and overall duration of infection manifested by febrile neutropenia; the incidence, severity and duration of severe neutropenia (ANC < 500/mm3); the incidence and overall duration of hospital admissions; and the number of reported days of antibiotic use.
PURPOSE:To obtain a cosmetic having low skin irritation and high safety and giving excellent feeling to the skin by compounding a cosmetic raw material produced by coating cosmetic raw material powder with a liquid mixture of hydrolyzed conchiolin and a humectant polymeric substance. CONSTITUTION:Hydrolyzed conchiolin is dissolved in a humectant polymeric substance (e.g. hyaluronic acid or collagen) compatible with the hydrolyzed conchiolin. If necessary, purified water is added and stirred in the above dissolution process. Powder such as titanium oxide or talc is added to the solution to obtain powder coated with hydrolyzed conchiolin and humectant polymeric substance and the coated powder is used as a raw material for the objective cosmetic. Tough and uniform coating can be applied to the powder to be compounded to cosmetic to enable the application of hydrolyzed conchiolin to an oil-based color cosmetic. Hydrophobic powder can be converted to hydrophilic by the coating to improve the dispersibility of the powder in an emulsion or water-based cosmetic.
A sterile secretome derived from the co-culture of M2-type macrophages and ASC (adipose stromal cells) containing 232,017 pg/mL TIMP-1. Participants will receive a total dose of 1,160,585.366 pg of TIMP-1 via IV infusion.
Chronic kidney disease (CKD) represents one of today's main public health problems. Serum creatinine measurement and estimation of the glomerular filtration rate (GFR) are the main tools for evaluating renal function. There are several equations to estimate GFR, and CKD-EPI equation (Chronic Kidney Disease - Epidemiology) is the most recommended one. There are still some controversies regarding serum creatinine measurement and GFR estimation, since several factors can interfere in this process. An important recent change was the removal of the correction for race from the equations for estimating GFR, which overestimated kidney function, and consequently delayed the implementation of treatments such as dialysis and kidney transplantation. In this consensus document from the Brazilian Societies of Nephrology and Clinical Pathology and Laboratory Medicine, the main concepts related to the assessment of renal function are reviewed, as well as possible existing controversies and recommendations for estimating GFR in clinical practice.
Treatment for removing silicones from the hair prior to dyeing or permanent waving comprises (a) applying a compsn. comprising (i) 1.0-20.0 wt.% dipropyleneglycolmonomethylether (I) and (ii) 0.1-80 wt.% of at least one anionic and/or ampholytic and/or nonionic and/or cationic surfactant (iii) at a pH in the acid region and (b) rinsing off with water. USE/ADVANTAGE - The compsns. give good removal of built-up silicone layers on the hair resulting from use of hair cosmetic preparations contg. these. The silicones cannot be removed with conventional shampoos and, if not removed, impede the penetration of dyeing and permanent waving agents into the hair so that these treatments give unsatisfactory results
PURPOSE: A novel gallotannin compound and a composition containing the same for antioxidation are provided to remove DPPH radial and superoxide radical and to enhance antioxidation. CONSTITUTION: A novel gallotannin compound is denoted by chemical formula 1 or 2. The compound is isolated from Acer ginnala. The gallotannin compound is 2,4-di-O-galloyl-1,5-anhydro-D-glucitol and 2,4-di-O-galloyl-1,5-anhydro-D-glucitol. A composition for anti-oxidation contains the gallotannin compound of chemical formula 1 or 2 as an active ingredient. The composition is a cosmetic and functional food composition. The cosmetic composition is manufactured in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, or spray.
PURPOSE:To provide the titled stench-preventive and deodorizing agent containing an extract of a specific plant, etc., having antibacterial activity against dermatic indigenous anaerobe, exhibiting excellent effect to suppress body odor such as underarm odor, foot odor, foul breath, etc., and having high safety. CONSTITUTION:A plant of Cupressaceae family belonging to Thujopsis genus (e.g. Thujopsis dolabrata, etc.), Thuja genus (e.g. Thuja standishii, etc.) or Juniperus genus (Juniperus rigida, Juniperus conferta, Juniperus chinensis, Juniperus chinensis var. procumbens, Juniperus chinensis var. sargenti, etc.) is extracted with a solvent, preferably ethanol, propylene glycol, water, hexane, etc., and the extract is used as a component of the objective agent. As an alter native, the leaves or twigs of the above plant is picked and crushed as is or after drying and the crushed product is used as a component. The crushed product is preferably sieved with a sieve passing particles of 2mm in diameter and the fraction passing through the sieve is used as the component. The amount of the extract or crushed product in the stench-preventive and deodorizing agent is preferably 0.001-50wt.% in the whole agent in terms of dried residue.
The MemFlex programme draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014), and was developed by clinical psychologists. MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training material is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks which are used throughout the workbook, and guides the participant in completion of these tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress.
The present invention relates to a method for preparing phosphodiesterase modulators using kaurane compounds. The phosphodiesterase is related to the treatment of cardiomyopathy, cardiac hypertrophy, pulmonary hypertension, normal tissue fibrosis reconstruction, chronic neurodegenerative diseases or other related diseases, and the structural formula of the phosphodiesterase is shown in a figure (I). Wherein: r1 represents hydrogen, hydroxy or alkoxy. R2 represents carboxyl, carboxylate, acyl halide, aldehydeA hydroxyl group and an ester, acrylamide, acyl or ether linkage group which can be hydrolyzed to generate a carboxyl group. R3, R4, R5, R6 and R8 represent oxygen, hydroxyl, hydroxymethyl and an ester group or alkoxy group which can be hydrolyzed to form hydroxymethyl. R7 represents a methyl group, a hydroxyl group, and an ester group or an alkoxy group which can be hydrolyzed to form a hydroxymethyl group. R9 represents methylene or oxygen.
OBJECTIVE: To investigate the effects of Clean-DM1 (C-DM1), a polyherbal formulation of Radix Scrophulariae, Radix Astragali, Rhizoma Atractylodis, and Radix Salviae Miltiorrhizae, on high-fat diet (HFD)-induced diabetes mice.
METHODS: The information about active components of C-DM1 extract and molecular mechanism was obtained from network pharmacology analysis. Main compounds of C-DM1 extract by high performance liquid chromatography-mass spectrometry (HPLC-MS) analysis were conducted for quality control. For in vivo study, mice were induced diabetes by HFD for 12 weeks. The mice in the normal group (Nor) were maintained with a regular diet and treated with saline by gavage. The HFD model mice were randomly divided into 3 groups, including a HFD diabetic model group, a C-DM1 extract-administered group (C-DM1, 500 mg/kg), and metformin-administered groups (Met, 500 mg/kg), 8 mice in each group. Food intake, body weight (BW), and fasting blood glucose (FBG) levels were recorded weekly for 4 weeks. After 4 weeks of treatment, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood glucose, low-density lipoprotein cholesterol (LDL-C) were determined using an automated clinical chemistry analyzer, and homeostatic model for assessing insulin resistance (HOMA-IR) levels and oral glucose tolerance test (OGTT) were detected. The histopathological changes of liver and pancreatic tissues were observed by hematoxylin-eosin staining. Insulin receptor substrate (IRS)/phosphatidylinositol 3 kinase (PI3K)/ protein kinase B (AKT) and adenosine 5'-monophosphate-activated protein kinase (AMPK) expressions in liver and pancreas tissues were detected by Western blot analysis.
RESULTS: HPLC-MS identified dihydroisotanshinone, dihydroisotanshinone I, cryptotanshinone, harpagoside, and atractyloside A in C-DM1 extract. The administration of C-DM1 extract significantly decreased body weight, calorie intake, and the levels of blood glucose and insulin in the diabetic mice (P<0.05 or P<0.01). The C-DM1 extract administration improved the impaired glucose tolerance and insulin resistance in the diabetic mice and significantly decreased the levels of LDL-C, ALT and AST (P<0.01). The C-DM1 extract inhibited the histopathological changes of fatty liver and hyperplasia of pancreatic islets in the diabetic mice. The C-DM1 extract significantly increased the phosphorylation of IRS, AKT, and AMPK and the expression of PI3K in pancreas and liver tissues (P<0.05 or P<0.01), which was consistent with the analysis results of network pharmacology.
CONCLUSION: C-DM1 extract improved diabetes symptoms in long-term HFD-induced mice by regulation of IRS/PI3K/AKT and AMPK expressions in pancreas and liver tissues, suggesting that C-DM1 formulation may help prevent the progression of T2DM.
Self-organizing spiral waves of excitation occur in many complex excitable systems. In the heart, for example, they are associated with the occurrence of fatal cardiac arrhythmias such as tachycardia and fibrillation, which can lead to sudden cardiac death. The control of these waves is therefore necessary for the treatment of the disease. In this letter, I present an innovative approach to control cardiac arrhythmias using low (nonfreezing) temperatures. This approach differs from all previous established techniques in that it involves no drugs, no genetic modification, no injection of foreign bodies, no application of voltage shocks (high or low, single or pulsed), and no curative damage to the heart. It relies on regional cooling of cardiac tissue to create a transient inhomogeneity in the electrophysiological properties. This inhomogeneity can then be manipulated to control the dynamics of the reentrant waves. This approach is, to my knowledge, the most sustainable theoretical proposal for the treatment of cardiac arrhythmias in the clinic.
PURPOSE:A light-weight dental metallic denture base, consisting of an electrocast metallic layer containing at least one of Ni and Co or further at least one of Cu,Ag,Au,In,B,Sn,P,Cr,Mo, etc., having improved reproducibility, compatibility, adhesion, holding property, etc. without falling off. CONSTITUTION:A dental denture base consisting of an electrocast metallic layer containing at least one of Ni and Co or further at least one of Cu,AG,Au,In,B, Sn,P,Cr,Mo,W,Mn,Fe,Ru,Rh,Pd and Pt. The electrocast metallic layer is prepared by dispersing and depositing a ceramic powder of a metallic oxide, metallic nitride and metallic boride, etc. simultaneously, and the metallic layer is partially or wholly coated with a highly corrosion-resistant metal consisting of Au,Pt, Ag and Cr as principal components. The electrocast metallic layer is electrodeposited on a model substrate impression part, etc. of an electrically conductive  material, e.g. an electrically conductive resin, prepared on the basis of an impression obtained from the oral cavity of a patient, and the electrodeposited  layer is then peeled from the substrate and finished to give the aimed dental metallic denture base.